A new breakthrough in stem cell therapy has showed great improvement among patients suffering from end-stage heart failure.
In a study published by the University of Utah, patients treated with stem cells harvested from their own bone marrow – also known as ixmyelocel-T cell therapy – had experienced 37 percent fewer cardiac events (including deaths and hospital admissions related to heart failure) than did a placebo control group.
“For the last 15 years everyone has been talking about cell therapy and what it can do. These results suggest that it really works,” says lead author and cardiac surgeon Amit N. Patel, M.D., M.S., director of Cardiovascular Regenerative Medicine at the University of Utah School of Medicine.
Further phase 3 clinical trials will be conducted to investigate whether the treatment can be used as an alternative to current therapy for heart failure patients in the future.
Don’t Fail To Share This Breakthrough…